Category: Press Releases

Intensity Therapeutics Strengthens Intellectual Property Portfolio with Issuance of Several New Patents in Asia and Australia

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune cell recognition of solid tumor cancers, today announced the receipt of patents protecting the Company’s technology and its lead product candidate, INT230-6, in China, Japan, Korea, Russia and Australia. All five countries have granted the Company a… Read more »

Intensity Therapeutics Highlights INT230-6 Data in Advanced Solid Tumors at Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced  additional data from a Phase 1/2 clinical study of INT230-6, the Company’s novel lead product candidate designed for direct intratumoral injection, and preclinical research highlighting the Company’s proprietary DfuseRxSM technology were presented in a poster session  at the Society for… Read more »

Intensity Therapeutics Raises $6.5 Million in Series B Financing

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced the completion of a $6.5 million Series B financing. Intensity plans to use the proceeds of the financing to advance the clinical development of lead product candidate INT230-6, a direct intratumoral injection that is currently being evaluated in a Phase… Read more »

Intensity Therapeutics Announces Preliminary Data from Clinical Study of INT230-6 in Advanced Solid Tumors

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced  preliminary data from a Phase 1/2 clinical study demonstrated that INT230-6, the Company’s novel lead product candidate designed for direct intratumoral injection, was well tolerated in patients with advanced solid tumors. The data were presented in a poster session on… Read more »

Intensity Therapeutics to Present Preliminary Data from Clinical Study of INT230-6 at Upcoming Medical Conferences

Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary immune cell-activating cancer treatments, today announced  that preliminary data from a Phase 1/2 clinical study of INT230-6 will be presented in poster sessions at the European Society for Medical Oncology (ESMO) 2018 Congress, which is being held October 19-23 in Munich, Germany, and the Society for… Read more »

Intensity Therapeutics, Inc. Announces Presentation on INT230-6 Clinical Study at the 2018 ASCO conference.

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary immune cell-activating cancer treatments, today announced that an abstract highlighting progress in the INT230-6 clinical development program will be presented as a poster at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 1-5 in Chicago. “The abstract being presented at… Read more »

Mark A. Goldberg, MD, Joins Intensity Therapeutics, Inc. Board of Directors

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced that Mark A. Goldberg, MD has been appointed to the Company’s Board of Directors effective May 1, 2018. Dr. Mark A. Goldberg recently served as president and COO of PAREXEL International, one of the world’s… Read more »

Intensity Therapeutics, Inc. Reports Positive Safety Data from On-going IT-01 Phase 1/2 Trial

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immune-based drug products for direct intratumoral injection, today announced completion of the first safety cohort (A) of the Company’s Phase 1/2 international clinical study evaluating lead product, INT230-6. Following intratumoral drug injections into superficial lesions in six patients with either ovarian, thyroid, head and… Read more »

Intensity Therapeutics Invited to Speak and Present at Upcoming Conferences

Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immune-based products, today announced that President and CEO Lewis H. Bender would be speaking on a CEO Panel titled: Raising Capital in the Current Market during the Immuno-Oncology 360° conference at the Roosevelt Hotel in New York City, NY February 7-9, 2018. IO360… Read more »

Intensity Therapeutics Issued New Patents for Technology Platform

Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office (PTO) issued the Company patent 9,636,406. In addition, the Company noted that the Australian PTO intends to grant Intensity patent 2013318338. “Intensity’s DfuseRxSM platform has identified our lead drug, INT230-6. This… Read more »